Purdue Pharma LP has secured a limited two-month period to renegotiate an agreement with members of the Sackler family. This comes as the maker of OxyContin and its ownership prepare to face a possible influx of civil opioid lawsuits. Earlier, the US Supreme Court invalidated a $6 billion settlement, which necessitated the current negotiations.
The new window affords Purdue Pharma a brief respite to formulate a revised plan that could potentially avert a protracted series of legal battles stemming from their role in the opioid crisis. Legal professionals should monitor the developments closely as the outcome could set significant precedents for mass torts and bankruptcy proceedings involving pharmaceutical companies.
For more detailed information, visit the original article on Bloomberg Law.